DexCom (DXCM) Stock Forecast & Price Target

DexCom is positioned for substantial growth driven by strategic momentum factors, including Medicare expansion and additional coverage wins in the non-insulin therapy (NIT) segment, which are expected to enhance the number of covered lives. The company's ongoing innovation, particularly the shift from 10-day to 15-day sensors and the introduction of an improved adhesive patch for the G7, is anticipated to lead to growing market adoption and retention among patients. Furthermore, increased operational leverage from a more productive sales force is set to support mid-teens revenue growth and over 20% EPS growth through 2028, indicating robust financial health and potential for expansion.

DexCom reported sensor revenue of $1.18 billion, reflecting a 20% year-over-year growth, but hardware revenue significantly declined by 31% to $34 million, signaling potential challenges in product diversification and overall demand. The company anticipates a sequential revenue decline of 6%-7% in Q1 2026, contributing to a forecasted fiscal year revenue guidance of $5.16 billion to $5.25 billion, which falls short of market expectations and suggests increasing deceleration in U.S. sales. Additionally, despite improvements in operational aspects of its CGM systems, the recent slowdown in growth and execution challenges could result in DexCom's shares trading at a discount compared to its peers, reflecting a cautious sentiment among investors.